Nektar Therapeutics Reports Third-Quarter 2026 Results, Advances Phase III Trials for Rezpegaldesleukin
Nektar Therapeutics updated investors on its third-quarter 2026 financial and clinical progress, highlighting $952.9 million in cash reserves and the late-stage development of its lead autoimmune drug.
🏢CompaniesPhoto: Motley Fool
Key points
- Cash and investments totaled $952.9 million at the end of the third quarter.
- ZENITH AD-2 study adapted to evaluate rezpegaldesleukin with topical corticosteroids.
- First top-line data readouts for atopic dermatitis expected in summer 2028.
Nektar Therapeutics moved its primary drug candidate, rezpegaldesleukin, into late-stage clinical development targeting several autoimmune dermatology conditions. During the third-quarter 2026 update, executives noted that the ZENITH AD-2 trial was adapted to test the medication alongside topical corticosteroids following international regulatory feedback, aiming to widen its future commercial label.
Financially, the firm finished the period holding $952.9 million in cash and investments. Leadership confirmed that this capital is adequate to sustain ongoing registrational studies focusing on atopic dermatitis and alopecia areata. The therapeutic approach utilizes a regulatory T-cell mechanism designed to restore immune balance across multiple inflammatory pathways, setting it apart from standard cytokine-blocking alternatives.
Chief Executive Officer Howard Robin pointed out that global phase III trials for atopic dermatitis are underway, while the alopecia areata study is slated to begin in December ahead of initial timelines. Initial top-line data readouts for atopic dermatitis are anticipated by the summer of 2028.
What to watch next: Monitor the commencement of the alopecia areata phase III study in December and any updates regarding regulatory milestones leading toward the 2028 data readouts.
Source Motley Fool — fool.com/earnings/call-transcripts/2026/11/13/nektar-nktr-q3-2026-e… ↗
Read next
🧠AI AnalysisCredo Technology Shares Fall Sharply Following September Earnings Report
Credo stock has declined 32% since its September 1 earnings release, trading significantly lower than its June record high.
🧠AI AnalysisArtificial Intelligence Dominates Market Focus Once Again
Market attention remains anchored entirely on the artificial intelligence sector as alternative topics take a back seat for another consecutive week.
🧠AI AnalysisNvidia Shares Slide as CEO Jensen Huang Resigns Following Scandal
Nvidia's market capitalization dropped to $3.93 trillion after co-founder Jensen Huang resigned following revelations of personal misconduct.
🧠AI AnalysisEmbraer Maintains Buy Rating Following Third-Quarter Performance
An independent analyst has reaffirmed a buy rating on Embraer shares following the release of the company's third-quarter financial results.
🧠AI AnalysisAnthropic Targets $1.4 Trillion Valuation in Upcoming Nasdaq Debut
AI developer Anthropic is set to list on the Nasdaq with a price range of $70 to $78 per share, potentially valuing the company at $1.4 trillion.
🧠AI AnalysisLowe's Positioned for Growth Amid Expanding Home Remodeling Budgets
An analysis of Lowe's Companies suggests the home improvement retailer is well-positioned to capitalize on increasing consumer spending in the remodeling sector.